CNBC: Actavis swoops in on Allergan for Salix buyout talks

Talk about a love triangle. Actavis ($ACT) made an advance toward Allergan ($AGN) last month, which the latter spurned because it thought it was close to landing Salix ($SLXP). Now, sources tell CNBC that Actavis has swooped in on Salix, with deal talks ongoing. Report

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.

Merck’s Keytruda went up against chemo in a head-to-head colorectal cancer battle—and won.